BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 21978390)

  • 1. The transhepatic endotoxin gradient is present despite liver cirrhosis and is attenuated after transjugular portosystemic shunt (TIPS).
    Benten D; Schulze zur Wiesch J; Sydow K; Koops A; Buggisch P; Böger RH; Gaydos CA; Won H; Franco V; Lohse AW; Ray SC; Balagopal A
    BMC Gastroenterol; 2011 Oct; 11():107. PubMed ID: 21978390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endotoxin and its binding proteins in chronic liver disease: the effect of transjugular intrahepatic portosystemic shunting.
    Kaser A; Ludwiczek O; Waldenberger P; Jaschke W; Vogel W; Tilg H
    Liver; 2002 Oct; 22(5):380-7. PubMed ID: 12390473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transjugular intrahepatic portosystemic shunt-placement increases arginine/asymmetric dimethylarginine ratio in cirrhotic patients.
    Siroen MP; Wiest R; Richir MC; Teerlink T; Rauwerda JA; Drescher FT; Zorger N; van Leeuwen PA
    World J Gastroenterol; 2008 Dec; 14(47):7214-9. PubMed ID: 19084936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic and splanchnic endothelin-1 plasma levels in liver cirrhosis before and after transjugular intrahepatic portosystemic shunt (TIPS).
    Nolte W; Ehrenreich H; Wiltfang J; Pahl K; Unterberg K; Kamrowski-Kruck H; Schindler CG; Figulla HR; Buchwald AB; Hartmann H; Ramadori G
    Liver; 2000 Feb; 20(1):60-5. PubMed ID: 10726962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endotoxin and tumor necrosis factor-receptor levels in portal and hepatic vein of patients with alcoholic liver cirrhosis receiving elective transjugular intrahepatic portosystemic shunt.
    Trebicka J; Krag A; Gansweid S; Appenrodt B; Schiedermaier P; Sauerbruch T; Spengler U
    Eur J Gastroenterol Hepatol; 2011 Nov; 23(12):1218-25. PubMed ID: 21971377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CXCL9 is a prognostic marker in patients with liver cirrhosis receiving transjugular intrahepatic portosystemic shunt.
    Berres ML; Asmacher S; Lehmann J; Jansen C; Görtzen J; Klein S; Meyer C; Strunk HM; Fimmers R; Tacke F; Strassburg CP; Trautwein C; Sauerbruch T; Wasmuth HE; Trebicka J
    J Hepatol; 2015 Feb; 62(2):332-9. PubMed ID: 25457205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effects of plasma lipopolysaccharide changes on platelet release of vascular endothelial growth factor and thromobospondin-1 in patients with cirrhotic portal hypertension after TIPS procedure].
    Chen SL; Xiao CJ; Jin SY; Li LH; Zhao JB
    Zhonghua Gan Zang Bing Za Zhi; 2022 Feb; 30(2):207-212. PubMed ID: 35359073
    [No Abstract]   [Full Text] [Related]  

  • 8. No difference in portal and hepatic venous bacterial DNA in patients with cirrhosis undergoing transjugular intrahepatic portosystemic shunt insertion.
    Mortensen C; Karlsen S; Grønbæk H; Nielsen DT; Frevert S; Clemmesen JO; Møller S; Jensen JS; Bendtsen F
    Liver Int; 2013 Oct; 33(9):1309-15. PubMed ID: 23763259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between endotoxemia and blood no in the portal circulation of cirrhotic patients: results of a pilot study.
    Bartimoccia S; Praktiknjo M; Nocella C; Schierwagen R; Cammisotto V; Jansen C; Cristiano L; Castellani V; Chang J; Carnevale R; Maiucci S; Uschner FE; Pignatelli P; Brol MJ; Trebicka J; Violi F
    Intern Emerg Med; 2024 Apr; 19(3):713-720. PubMed ID: 38409619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in plasma endothelin-1 and Big endothelin-1 induced by transjugular intrahepatic portosystemic shunts in patients with cirrhosis and refractory ascites.
    Martinet JP; Legault L; Cernacek P; Roy L; Dufresne MP; Spahr L; Fenyves D; Pomier-Layrargues G
    J Hepatol; 1996 Nov; 25(5):700-6. PubMed ID: 8938548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transjugular intrahepatic portosystemic shunt: short-term and long-term effects on hepatic and systemic hemodynamics in patients with cirrhosis.
    Lotterer E; Wengert A; Fleig WE
    Hepatology; 1999 Mar; 29(3):632-9. PubMed ID: 10051460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short- and long-term effects of the transjugular intrahepatic portosystemic shunt on portal vein thrombosis in patients with cirrhosis.
    Luca A; Miraglia R; Caruso S; Milazzo M; Sapere C; Maruzzelli L; Vizzini G; Tuzzolino F; Gridelli B; Bosch J
    Gut; 2011 Jun; 60(6):846-52. PubMed ID: 21357252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating Elastin Fragments Are Not Affected by Hepatic, Renal and Hemodynamic Changes, But Reflect Survival in Cirrhosis with TIPS.
    Nielsen MJ; Lehmann J; Leeming DJ; Schierwagen R; Klein S; Jansen C; Strassburg CP; Bendtsen F; Møller S; Sauerbruch T; Karsdal MA; Krag A; Trebicka J
    Dig Dis Sci; 2015 Nov; 60(11):3456-64. PubMed ID: 26138655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transjugular intrahepatic portosystemic shunt (TIPS) augments hyperinsulinemia in patients with cirrhosis.
    Kaser S; Föger B; Waldenberger P; Nachbaur K; Propst A; Jaschke W; Vogel W; Patsch JR
    J Hepatol; 2000 Dec; 33(6):902-6. PubMed ID: 11131451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Scintigraphic evaluation of hepatic blood flow after intrahepatic portosystemic shunt (TIPS).
    Menzel J; Schober O; Reimer P; Domschke W
    Eur J Nucl Med; 1997 Jun; 24(6):635-41. PubMed ID: 9169570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of transjugular intrahepatic portosystemic shunt (TIPS) on quantitative liver function tests.
    Baron A; Gulberg V; Sauter G; Waggershauser T; Reiser M; Gerbes AL
    Hepatogastroenterology; 1998; 45(24):2315-21. PubMed ID: 9951915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short-term effects of transjugular intrahepatic portosystemic shunt (TIPS) on functional liver plasma flow in patients with advanced cirrhosis.
    Bar F; Battista S; Garello E; Grosso M; Spalluto F; Zanon E; Torchio M; Molino G
    Liver; 1998 Aug; 18(4):245-50. PubMed ID: 9766819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Surgical portosystemic shunts versus transjugular intrahepatic portosystemic shunt for variceal haemorrhage in people with cirrhosis.
    Brand M; Prodehl L; Ede CJ
    Cochrane Database Syst Rev; 2018 Oct; 10(10):CD001023. PubMed ID: 30378107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of TIPS on liver perfusion measured by dynamic CT.
    Weidekamm C; Cejna M; Kramer L; Peck-Radosavljevic M; Bader TR
    AJR Am J Roentgenol; 2005 Feb; 184(2):505-10. PubMed ID: 15671371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantification of intrahepatic portosystemic shunting after placement of a transjugular intrahepatic portosystemic shunt.
    Walser EM; Harris VM; Harman JT; Park HM; Siddiqui AR
    J Vasc Interv Radiol; 1996; 7(2):263-7. PubMed ID: 9007808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.